Navigation Links
VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
Date:1/28/2010

BEDFORD, Mass., Jan. 28 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany.  The patent acquisition includes over 45 issued patents worldwide covering a wide range of fluorescence agent constructs and imaging methods, and consolidates VisEn's patent and technology leadership position in the emerging markets of fluorescence imaging from preclinical research through clinical molecular diagnostics.

"We have closely tracked the very high quality of Bayer Schering Pharma's fluorescence agent technologies and extensive patent portfolios over the last decade, and we are pleased to now integrate these platforms into VisEn's programs," said Kirtland Poss, President and CEO of VisEn Medical.  "The acquisition of these assets significantly expands VisEn's patent coverage of in vivo fluorescent imaging agents, and adds to our R&D capability and pipeline of preclinical agent products and clinical imaging agents going forward."

With this acquisition, VisEn's intellectual property portfolio covering fluorescence imaging agents now includes over 150 patents and patent applications worldwide.  The collective patent estate provides comprehensive coverage of a broad range of core agent components and chemistries, as well as key preclinical and clinical applications and methods.  Included in the acquired portfolio are key patents covering physiologic agents, bioconjugates and targeted fluorescence agents, and certain activatable imaging agents for measurement of diverse biomarker activity in living systems.  With the addition of these new platforms, VisEn plans to further expand the aggressive development of its preclinical agent product offerings, as well as its clinical imaging agent pipeline and related programs.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT™) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical companies and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical research and clinical program areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

RELATED LINKS
http://www.visenmedical.com

'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
4. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
5. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. U.S. Preventive Medicine Acquires Specialty Disease Management
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
11. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... VMS BioMarketing as senior vice president of sales, announced Andrea Heslin Smiley , ... the company,s business development and sales team, exploring new opportunities for VMS to empower ... ... ... ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... Georgia State University College of Law is ... Answering to the increasing demand for curricular specializations, the Certificate in Intellectual Property ... land use law. ,  , “The demand for lawyers with specific knowledge in ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is a ... on long-term patient survival, reports a team of UPMC researchers in the largest ... the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will hopefully ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, ... public. , Dr. Maisel, founder of Retina Group of New York , ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
(Date:5/26/2016)... San Rafael, CA (PRWEB) , ... May 26, ... ... Studio will be offering campers a multitude of activities from daily practices, arts ... and self-confidence. , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds ...
Breaking Medicine News(10 mins):